Avacta has entered into an exclusive distribution agreement with Medusa19 Limited (‘Medusa19’) for direct-to-consumer sales of a saliva-based rapid test for the COVID-19 antigen.
Having established the giant and immediate global market opportunity for such a product, significant investment that Medusa19 is proposing to make along with its team’s track records, provides Avacta’s CEO with confidence that the commercial impact of this partnership could be ‘very significant’ for his Group.
Avacta’s decision to rapidly enter into such an agreement reflects its understanding of the importance of being an early mover, capable of offering the highest quality product along with the necessary manufacturing capacity through a global distribution hub capable of satisfying international consumer demand in a marketplace that might otherwise become saturated with ‘me too’ players.
Subject to regulatory approval, Avacta and its development partner, Cytiva (formerly GE Healthcare Life Sciences), have now positioned themselves for global commercialisation in the direct to consumer market. Avacta continues to work to establish other routes to market with additional partners.
We would draw your attention to the various disclaimers in the document both at the beginning and at the end of the note. Retail clients (as defined by the rules of the FCA) must not rely on the research document. In particular you should note that the research document is a non-independent marketing communication. The analyst who has prepared the research is aware that TPI provides research to Avacta Group plc. Accordingly the research has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibitions on dealing ahead of its dissemination.
The information in the document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.
Copyright © 2020 Turner Pope Investments (TPI) Limited, all rights reserved.
